Cagrilintide, a long-acting analogue of the hormone amylin, presents a promising new approach to tackling obesity.  Unlike many weight-loss drugs that only target one mechanism, cagrilintide works on multiple fronts. It suppresses appetite by promoting feelings of fullness (satiety) and slows down gastric emptying, making people feel full for longer periods of time. 

Early trials of cagrilintide have shown that it leads to significant weight loss compared to placebo and even other peptides like liraglutide, which is currently used for obesity treatment. In one study, participants taking cagrilintide lost up to 10.8% of their body weight over 26 weeks, outperforming those on liraglutide.

Sustained weight loss like this can help break the cycle of yo-yo dieting.